Peter Gelinas

Chief Technology Officer CoRegen

Seminars

Thursday 25th March 2027
Addressing Gene-Edited Treg Manufacturing Bottlenecks From Early Development Through to Clinical Readiness
1:00 pm
  • Navigating donor-to-donor variability when developing manufacturing processes to improve consistency and support future scale-up initiatives
  • Optimizing analytical strategies and characterization approaches to ensure the right assays are in place for evaluating gene-edited Treg products throughout development
  • Balancing manufacturing scalability, product quality, and phenotypic functionality while preparing Treg therapies for successful clinical translation and broader commercialization
Peter Gelinas